Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy

Clinical Endocrinology

Volumn 76, Issue 4, 2012, Pages 577-581

  Verburg, Frederik A ^a,b   Smit, Johannes W A ^c   Grelle, Inge ^a   Visser, Theo J ^d   Peeters, Robin P ^d   Reiners, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEIODINASE TYPE 1; DEIODINASE TYPE 2; DEIODINASE TYPE 3; ENZYME; IODINE 131; LEVOTHYROXINE; LIOTHYRONINE; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; DIFFERENTIATED THYROID CANCER; DOWN REGULATION; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LIOTHYRONINE BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; THYROID HORMONE METABOLISM; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT OUTCOME; UPREGULATION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE; YOUNG ADULT;

EID: 84857850507     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04262.x     Document Type: Article

References (14)

1. Pacini, F., Schlumberger, M., Dralle, H. et al. (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology, 154, 787-803. (Pubitemid 43997716)
2. Cooper, D.S., Doherty, G.M., Haugen, B.R. et al. (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-1214.
3. Hovens, G.C., Stokkel, M.P., Kievit, J. et al. (2007) Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 92, 2610-2615. (Pubitemid 47037365)
4. Jonklaas, J., Sarlis, N.J., Litofsky, D. et al. (2006) Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid, 16, 1229-1242. (Pubitemid 46080167)
5. Heemstra, K.A., Hamdy, N.A., Romijn, J.A. et al. (2006) The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma. thyroid, 16, 583-591.
6. Smit, J.W., Eustatia- Rutten, C.F., Corssmit, E.P. et al. (2005) Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism, 90, 6041-6047.
7. Laurberg, P., Vestergaard, H., Nielsen, S. et al. (2007) Sources of circulating 3,5,3′-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. Journal of Clinical Endocrinology and Metabolism, 92, 2149-2156. (Pubitemid 46997114)
8. Weetman, A.P., Shepherdley, C.A., Mansell, P. et al. (2003) Thyroid over-expression of type 1 and type 2 deiodinase may account for the syndrome of low thyroxine and increasing triiodothyronine during propylthiouracil treatment. European Journal of Endocrinology, 149, 443-447.
9. Verburg, F.A., Mader, U., Luster, M. et al. (2008) Primary tumor diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clinical Endocrinology, 71, 291-297.
10. Verburg, F.A., Mader, U., Luster, M. et al. (2009) Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases. European Journal of Endocrinology, 160, 619-624.
11. Peeters, R.P., Wouters, P.J., van Toor, H. et al. (2005) Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. Journal of Clinical Endocrinology and Metabolism, 90, 4559-4565. (Pubitemid 41159343)
12. Peeters, R.P., Wouters, P.J., Kaptein, E. et al. (2003) Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. Journal of Clinical Endocrinology and Metabolism, 88, 3202-3211. (Pubitemid 36877495)
13. Brokken, L.J., Wiersinga, W.M. & Prummel, M.F. (2003) Thyrotropin receptor autoantibodies are associated with continued thyrotropin suppression in treated euthyroid Graves' disease patients. Journal of Clinical Endocrinology and Metabolism, 88, 4135-4138. (Pubitemid 37153710)
14. Brokken, L.J., Scheenhart, J.W., Wiersinga, W.M. et al. (2001) Suppression of serum TSH by Graves' Ig: evidence for a functional pituitary TSH receptor. Journal of Clinical Endocrinology and Metabolism, 86, 4814-4817. (Pubitemid 33020525)